<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01469078</url>
  </required_header>
  <id_info>
    <org_study_id>P-Monofer-PK-CKD-05</org_study_id>
    <nct_id>NCT01469078</nct_id>
  </id_info>
  <brief_title>Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered as Single Bolus Injections in Subjects With Stage 5 Chronic Kidney Disease on Dialysis Therapy (CKD-5D)</brief_title>
  <official_title>Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered as Single Bolus Injections in Subjects With Stage 5 Chronic Kidney Disease on Dialysis Therapy (CKD-5D) (PK-CKD-05)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmacosmos A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ClinSmart</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Pharmacosmos A/S</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess Pharmakokinetic properties of iron isomaltoside 1000&#xD;
      (Monofer®) in doses of 100 mg, 200 mg or 500 mg in subjects with Stage 5 Chronic Kidney&#xD;
      Disease on Dialysis Therapy (CKD-5D).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of changes in Iron pharmacokinetic parameters from plasma/serum concentration profile</measure>
    <time_frame>From exposure to 7 days post-exposure</time_frame>
    <description>The follwoing parameter will be determined: AUC0-t, AUC, Cmax, Tmax, Ke, and T1/2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in pharmacodynamic parametres</measure>
    <time_frame>From 0 hours to 4, 8, 24, 48, 72 hours post-exposure and end of study visit</time_frame>
    <description>Changes in the following parametres will be determined: Hemoglobin (Hb), Reticulocyte Count, Reticuloycyte Hemoglobin Content (CHr), Ferritin, Total Iron Binding Capacity (TIBC) and Transferrin Saturation (TfS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety evaluation</measure>
    <time_frame>From screening to 7 days post-exposure</time_frame>
    <description>The following parameters will be evaluated: Laboratory safety variable, physical examination, vital signs and Electrocardiogram (ECG)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>100 mg Monofer®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>200 mg Monofer®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>500 mg Monofer®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Monofer®</intervention_name>
    <description>Single Bolus Injections</description>
    <arm_group_label>100 mg Monofer®</arm_group_label>
    <arm_group_label>200 mg Monofer®</arm_group_label>
    <arm_group_label>500 mg Monofer®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men and women, aged more than 18 years.&#xD;
&#xD;
          2. Weight above 50 kg.&#xD;
&#xD;
          3. Subjects diagnosed with CKD-5D and on dialysis therapy for at least 90 days prior to&#xD;
             inclusion.&#xD;
&#xD;
          4. Serum ferritin ≤ 800 ng/mL.&#xD;
&#xD;
          5. Transferrin Saturation ≤ 35%.&#xD;
&#xD;
          6. Life expectancy beyond 12 months by Principal Investigator's judgement.&#xD;
&#xD;
          7. Hb concentrations ≥10.0 g/dL and ≤12.5 g/dL both at Screening Visit 1a and at&#xD;
             Screening Visit 1b (Screening Visit 1a and Visit 1b must be separated by at least 1&#xD;
             week).&#xD;
&#xD;
          8. Erythropoiesis Stimulating Agent (ESA) treatment (to be kept constant during the study&#xD;
             period and for 4 weeks prior to inclusion with only one missed dose to be allowed&#xD;
             during this pre-entry period).&#xD;
&#xD;
          9. Subjects in maintenance iron therapy with average iron administration ≤ 100 mg/week&#xD;
             for 4 weeks prior to inclusion and willingness to switch to investigational product.&#xD;
&#xD;
         10. Willingness and ability to participate after informed consent (including HIPAA, if&#xD;
             applicable).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Anemia caused primarily by other factors than renal related anemia.&#xD;
&#xD;
          2. Iron overload or disturbances in utilization of iron (e.g. hemochromatosis and&#xD;
             hemosiderosis).&#xD;
&#xD;
          3. Difference of Hb ≥ 1.0 g/dL between Screening Visits 1a and 1b.&#xD;
&#xD;
          4. Known hypersensitivity to any excipients in the investigational drug products.&#xD;
&#xD;
          5. Subjects with a history of multiple allergies.&#xD;
&#xD;
          6. Decompensated liver cirrhosis and history of hepatitis B or C [Alanine&#xD;
             Aminotransferase (ALT) &gt; 3 times upper limit of normal].&#xD;
&#xD;
          7. Acute or chronic infections (assessed by clinical investigator judgment), supported by&#xD;
             White Blood Cells (WBC) and C-Reactive Protein (CRP).&#xD;
&#xD;
          8. Rheumatoid arthritis with symptoms or signs of active joint inflammation.&#xD;
&#xD;
          9. Pregnant or nursing women.&#xD;
&#xD;
         10. Women of child bearing potential who are not using safe contraceptive methods (e.g.&#xD;
             intrauterine device, oral contraceptives or surgically sterilized) or who are planning&#xD;
             to become pregnant within the study period.&#xD;
&#xD;
         11. Blood transfusion within the previous 12 weeks.&#xD;
&#xD;
         12. Planned elective surgery during the study where significant blood loss is expected.&#xD;
&#xD;
         13. Participation in any other clinical trial within 3 months prior to screening.&#xD;
&#xD;
         14. Untreated Vitamin B12 or folate deficiency.&#xD;
&#xD;
         15. Any other medical condition that, in the opinion of Principal Investigator, may cause&#xD;
             the subject to be unsuitable for the completion of the study or place the subject at&#xD;
             potential risk from being in the study. Examples include Uncontrolled Hypertension,&#xD;
             Unstable Ischemic Heart Disease or Uncontrolled Diabetes Mellitus.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>November 2012</verification_date>
  <study_first_submitted>October 27, 2011</study_first_submitted>
  <study_first_submitted_qc>November 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2011</study_first_posted>
  <last_update_submitted>November 7, 2012</last_update_submitted>
  <last_update_submitted_qc>November 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Kidney Disease</keyword>
  <keyword>CKD stage 5</keyword>
  <keyword>Iron deficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

